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Abstract
Endometriosis is an inflammatory disease of women of reproductive age featured
by the presence of ectopic endometrium and is strongly related to infertility.
Galectins, carbonhydrate-binding proteins, have been found to have pro- or anti-
inflammatory roles in the reproductive tract and in pathological conditions
concerning infertility. Galectin-1, which is expressed at endometrium and decidua,
plays a major role in implantation and trophoblast invasion. Also, the
neuropeptides, corticotropin releasing hormone (CRH) and urocortin (UCN) and
their receptors are expressed in eutopic and ectopic endometrium showing a
differential expression pattern in endometriotic women compared to healthy ones.
The aim of this study was to examine the galectin-1 expression in endometriotic
lesions and compare its expression in eutopic endometrium of endometriotic and
healthy women. Furthermore, we examined the effect of CRH and UCN in galectin-
1 expression in Ishikawa cell line and macrophages and investigated the
implication of CRHR1 in these responses. Eutopic and ectopic endometrium
specimens, Ishikawa cell line and mice macrophages were used.
Immunohistochemistry and western blot analysis were performed in order to
identify galectin-1 expression in ectopic and eutopic endometrium of women with
and without endometriosis and the regulatory effect of CRH and UCN on galectin-1
expression. This study presents for the first time that galectin-1 is overexpressed in
endometriotic lesions compared to eutopic endometrium of endometriotic women
and is more abundantly expressed in eutopic endometrium of disease women
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compared to healthy ones. Furthermore, it is shown that CRH and UCN upregulate
galectin-1 expression in Ishikawa cell line and macrophages and this effect is
mediated through CRHR1. These results suggest that galectin-1 might play an
important role in endometriosis pathology and infertility profile of women suffering
from endometriosis by being at the same time regulated by CRH and UCN
interfering in the immune disequilibrium which characterizes this pathological
condition.
Introduction
Endometriosis is a benign chronic disease affecting 10% of women of
reproductive age. Endometriosis, featured by stromal and epithelial ectopic
endometrial tissue [1–5] is accompanied with adhesion formation, pelvic pain and
infertility. Although its pathogenesis has not been completely identified,
endometriosis has been characterised as an estrogen-dependent chronic
inflammatory disease [6–8]. Endocrine/paracrine influences and immunological
aspects have also been linked to this disease. In addition, several growth factors,
cytokines, immune cells and hormones have been proposed as involved in the
pathophysiology of endometriosis-related infertility, via altering both the eutopic
and the ectopic endometrium [3, 9].
Galectins are carbonhydrate-binding proteins which bind b-galactoside [10].
Galectins have strongly been implicated in inflammation, autoimmunity and
cancer and have been thought to be useful anti-inflammatory targets. As far as the
immune system is concerned, galectins are important regulators of activated
macrophages and activated B cells. They also play a vital role in T cell homeostasis
and survival. Galectins are widely expressed by reproductive tissues. Galectin-1, -
3, -9, -15 have been found to be expressed in human endometrium and decidua,
while galectin-1(gal-1) has been also found to be expressed by endometrial
stromal cell in humans [11–13]. Galectins have been reported as potential
contributors to endometrial immune system regulation; galectins seem to play a
vital role in leukocyte regulation by interfering into cell adhesion, migration and
chemotaxis [14]. Interestingly, decidual expression of gal-1 is regulated by
progesterone, while galectin-1 increases progesterone concentrations. This
positive feedback between galectin-1 and progesterone is considered of great
importance in pregnancy maintenance [15]. Gal-1 expression levels in
endometrium vary during the menstrual cycle, being increased significantly at late
secretory phase of endometrium and in the decidua. At the same time a very
interesting gal-1 expression pattern in trophoblastic tissue has been shown [13].
Gal-1 is also synthesized, prior to implantation, in the trophoectoderm of
blastocysts and has also been recently found to participate in human trophoblast
cell invasion machinery [16]. It is thus clear, that gal-1 is an important
contributor to a successful pregnancy.
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As endometriosis is characterized by the expression of several proteins
including growth factors, integrins, cadherins and lectins that regulate cell
migration, invasion, angiogenesis, immune functions and apoptosis, galectins are
expected to play an important role in this inflammatory disease. So far, only
galectin-3 has been found to be overexpressed in various forms of endometriosis
compared to eutopic endometrium of women with endometriosis and to be more
highly expressed in the eutopic endometrium of women with endometriosis
compared to the eutopic endometrium of women without endometriosis [17].
Taking into consideration that gal-1 has a vital role at inflammatory sites, in
implantation and decidualization as well, combined with the fact that
endometriosis is accompanied with inflammation and infertility, we thought that
it would be interesting to investigate and compare gal-1 expression in eutopic
endometrium of both healthy and disease women and to compare gal-1
expression levels in eutopic and ectopic endometrium of disease women trying to
further clarify gal-1 role in endometriosis.
Corticotropin Releasing Hormone (CRH) is a 41-amino acid neuropeptide,
synthesised in the hypothalamus, regulating the hypothalamus-pituitary-adrenal
axis [18, 19]. CRH expression and biological functions are mediated by its
membrane receptors, CRH-R1 (a, b, c, c-h) and CRH-R2 (a, b, c) [20–22]. CRH
receptors are also activated by other endogenous agonists, such as urocortin
(UCN), which is a 40-amino acid peptide belonging to the corticotropin-releasing
hormone family and is structurally related to CRH [23–25]. Apart from the
central nervous system, CRH and its receptors are expressed in several sites of the
female reproductive system, including the endometrial glands, decidualized
stroma, trophoblast, syncytiotrophoblast and placental decidua [26–28].
Moreover, CRH and UCN are secreted at inflammatory sites, acting as
proinflammatory factors [18–21, 23, 24, 29, 30]. Reproductive CRH has been
shown to serve as an autocrine and paracrine modulator and to participate in
decidualization, embryo implantation and maintenance of human pregnancy
[27, 31–39]. In addition, CRH and UCN mRNA have been found to be expressed
by endometriotic cells, while endometriotic lesions show a strongly positive
staining reaction for CRH and UCN [40]. The expression and function of CRH
and UCN have also been found to be impaired in eutopic endometrium of women
with endometriosis [41]. Moreover, we have recently shown that CRH and UCN
receptor subtypes CRHR1b and CRHR2a are expressed in endometriotic sites and
that they are more strongly expressed in eutopic endometrium of women with
endometriosis compared to healthy women endometrium at mRNA and protein
level. CRH, UCN, CRHR1 and CRHR2 mRNA were also more highly expressed in
ectopic rather than eutopic endometrium in women with endometriosis. These
data indicate that CRH and UCN might play an immunoregulatory role in
endometriotic sites [42]. So, it would be of quite interest to investigate if and how
these neuropeptides regulate proteins (such as galectins) participating in fetal-
maternal crosstalk and inflammatory pathological situations such as endome-
triosis.
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Considering all the above, the aim of this study was i) to identify the gal-1
expression in the eutopic and the ectopic endometrium of women with
endometriosis and compare its expression with the eutopic endometrium of
healthy women and ii) to examine whether and how CRH and UCN regulate gal-1
expression in eutopic endometrium and macrophages.
Materials and Methods
Tissue sample collection
Biopsy specimens of endometrium (at proliferative, early secretory and secretory
phase, confirmed by the progesterone levels of the women) were taken from
healthy women (10 patients) undergoing hysteroscopy for diagnostic reasons due
to spontaneous spotting haemorrhage. When comparing protein expression levels
in eutopic endometrium of healthy and disease women, only eutopic
endometrium at the secretory phase was used. They were all healthy apart from 3/
10 having small polyps, as their hysteroscopy results showed. Eutopic and ectopic
endometrial tissue biopsies (stage III and IV) at secretory phase, as it was
confirmed by the progesterone levels of the patients, were obtained from 16
patients diagnosed with endometriosis on different sites (peritoneal nodule,
rectovaginal nodule, rectouterine nodule, right and left ovarian cyst endome-
triosis, left and right uterosacral legiment nodule), sharing all the same pathology,
in the Department of Obstetrics and Gynaecology, St Bartholomew’s Hospital of
Queen Mary University, London, UK (Research Ethics Committee Reference
Number: 05/Q0604/44). This research protocol was approved by the Ethics
Committee of Queen Mary University, London, UK. All participants provided
their written informed consent to participate. It is important to notice that the
most critical reproductive hormone levels of both healthy and endometriotic
patients did not affect the outcome of our research protocols as they ranged
among: FSH levels (day 3 of the menstrual cycle): healthy patients 6–8 mlU/ml,
endometriotic patients 7–9 mlU/ml, E2 levels (day 3 of the menstrual cycle):
healthy patients 45¡7 pg/ml, endometriotic patients 50¡11 pg/ml and
Progesterone levels (day 21 of the menstrual cycle): healthy patients 17¡2 ng/ml,
endometriotic patients 15¡3 ng/ml. In addition, all the detailed inclusion and
exclusion criteria taken into consideration for tissue sample collection are the
following. Inclusion criteria for tissue sample collection: i) Reproductive aged
women, ii) normal steroid hormone profile, iii) women undergoing hysteroscopy
for diagnostic reasons due to spontaneous spotting haemorrhage, iv) stage III and
IV endometriosis diagnosed during surgery. Exclusion criteria for tissue sample
collection; i) women that have received hormonal treatment at least three months
prior to surgery, ii) women under treatment for other pathologies, iii) women
with possible endometrial hyperplasia, iv) women suffering from other
endometrial pathologies diagnosed during hysteroscopy.
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Cell culture
Ishikawa cell line culture
Ishikawa cell line: Human endometrial adenocarcinoma cell line. Ishikawa cells
show characteristics of glandular and luminal epithelium and express many of the
enzymes, proteins and steroid receptors present in normal endometrium, which
makes them suitable for the study of endocrine signaling in endometrium.
Ishikawa cells are widely considered a good model for studying endometrium
function. Ishikawa cell line was a generous gift from Prof Udo Jeschke, bought
from the European Collection of Cell Cultures (ECACC, Salisbury, UK). Ishikawa
cell line was cultured in DMEM Glutamax supplemented with 10% FBS
(inactivated at 56 C̊ for 1 hr), 1% Penicilline/Streptomysin, 1% Sodium Pyruvate
and 1% Anti – Mycotic at a humidified incubator in a 5% CO2 atmosphere at
37 C̊. The medium used to be changed every 48 hrs.
Isolation and culture of murine bonne marrow macrophages (BMMs)
BMMs were derived from at least three 6 to 8 week old mice per experiment. Cells
were cultured on bacteriological plastic plates at 106 cells/ml in macrophage
growth medium consisting of RPMI 1640 (GIBCO-Invitrogen Ltd., Paisley, UK),
1 mM sodium pyruvate (GIBCO), 1x non-essential amino acids (GIBCO),
0.029 mM 2-mercaptoethanol (Sigma), 10% heat-inactivated FCS (GIBCO)
supplemented with 10% L cell-conditioned medium as a source of CSF-1. After 3
days, non-adherent cells were collected and either cryogenically stored in FBS
containing 10% DMSO or cultured at 6–86105 cells/ml on petril dishes and
cultured for 4 days before use. Cells were detached using EDTA, centrifuged at
10006g, resuspended in macrophage growth medium and cultured for the
experiments. All results were obtained from cells that had been cultured for no
longer than 10 days after dissection. In all experiments, the medium was changed
to macrophage starvation medium (macrophage growth medium without L-cell-
conditioned medium) 16–20 h prior to experiments.
Cells incubated with peptides
Cells were incubated with the appropriate peptide according to each experimental
protocol, before the protein lysate extraction protocol. CRH peptide (Tocris R&D
Systems), stock of 1024 M: 1027 M final concentration in cells - medium. UCN
peptide (Sigma-Aldrich), stock of 1024 M: 1027 M concentration in cells –
medium. The incubation of cells with CRH and UCN peptide was for 0, 2, 8,
24 hrs. Antalarmin, stock of 1023 M: 1026 M final concentration in cells –
medium together with CRH peptide and incubation of cells for 8, 24 hrs.
Cell protein lysates extraction
Protein lysate has been extracted from Ishikawa cell line and mice macrophages
according to the following protocol: After cells had been treated with the
appropriate peptides added with 1x PBS. General Lysis Buffer (50 mM Tris,
pH 7.5, 1 mM EDTA, 150 mM M NaCl, 1% Igepal, 50 mM NaF and on day of
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cell lysis the following inhibitors: 1:1000 of stock leupeptin 10 Mm, 1:100 of stock
100 mM PMSF (in isopropanol), 10 mg/ml aprotinin, 1:100 of stock 100 mM
Na4V03 were added) was added cells were scabbed and placed in a tube on ice for
20 min by continuous vortexing. Cells were then centrifuged at 13000 rpm for
5 min. The supernatant at this step is the protein lysate. The whole quantity was
removed in a new tube and placed on ice till used. The protein concentration was
determined using Bradford protein assay method and a spectrophotometer,
measuring proteins at 495 nm. Equal quantities of proteins had been used for
western blotting analysis. 100 mg of protein is mixed with 4x sample buffer (Tris,
b-mercaptoethanol, SDS, glycerol, 0.008 gr BPB) and boiled at a heat blocker at
95 C̊ for 5 min. Samples were stored at 220 C̊, till to be used for western blotting
analysis.
Tissue protein extraction
Firstly, the T-PER (Thermoscientific) mix by adding inhibitors (as described
above) was prepared and 1, 5 ml of T-PER mix was added in 0.100 gr of tissue for
homogenization. After that, centrifugation at 10.000 g for 10 min followed. The
supernatant at this step is the protein lysate. The supernatant was removed very
carefully in new tubes and placed on ice till used. The protein concentration was
determined using Bradford protein assay method and a spectrophotometer,
measuring proteins at 495 nm. Proteins are mixed with Biorad (1 ml Biorad21
Biorad: 5 water for injection H2O2+5 ml of protein extract) are measured at
495 nm. Equal quantities of proteins had been used for western blotting analysis.
100 mg of protein is mixed with 4x sample buffer (Tris, b-mercaptoethanol, SDS,
glycerol, 0.008 gr BPB) and boiled at a heat blocker at 95 C̊ for 5 min. Samples
were stored at 220 C̊, till to be used for western blotting analysis.
Western blotting analysis
100 mg of proteins were extracted from Ishikawa cell line, macrophages, healthy
women’s eutopic endometrium (10 patients) and eutopic endometrium and
endometriotic tissue from endometriotic patients (16 patients), followed by SDS-
PAGE analysis in 10% acrylamide gel, and electrotransfer onto a nitrocellulose
membrane. The membrane was blocked in 5% skim milk powder in 0.1% Tris-
buffered saline/Tween for 20 min. The membrane was then incubated with
galectin-1 (rabbit polyclonal anti-galectin-1 antibody, Abcam) at a dilution of
1:1000, followed by incubation goat anti-rabbit IgG AP132P (Chemicon
International, multipore). GAPDH (rabbit GAPDH antibody 14C10, Cell
signalling) was used as a house keeping gene. Band intensities of protein of
interest were normalized with band intensities of GAPDH and expressed as
arbitrary units (a.u.).
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Immunohistochemical analysis
Formalin-fixed, paraffin-embedded tissue sections (4 mm thick) of eutopic
endometrium from 16 patients were deparaffinized in xylene and rehydrated
through graded concentrations of ethanol. Antigen retrieval (350W, 3 cycles,
5 min each in citrate buffer: 10% citric acid mix29 ml citric acid and 41 ml
sodium citrate in 450 ml ddH20) was followed. After inhibition of endogenous
peroxidases with 3% H2O2 (5 min), unspecific antibody binding was blocked with
10% power block (BioGenex Lig DAB substrate Pack, BioGenex Laboratories Inc,
Fremont, CA, USA) for 10 min. Serial sections were then incubated with primary
antibody against human galectin-1 (rabbit polyclonal anti-galectin-1 antibody,
Abcam). Both blocking as well as detection and visualization of staining were
performed by using the BioGenex Supersensitive link-label Detection System
(BioGenex Laboratories Inc, Fremont, CA, USA) followed by the BioGenex Lig
DAB substrate Pack (BioGenex Laboratories Inc, Fremont, CA, USA), according
to the manufacturer’s protocols. Finally the slides were counterstained with
Mayer’s heamatoxylin (Dako, Carpinteria, CA, USA) for 3 min, washed in tap
water and covered using Glycergel (Dako, Carpinteria, CA, USA). Negative
controls were performed by replacing the primary antibody with normal rabbit
IgG as isotype control. The sections were examined by light microscopy. The
intensity and distribution of the staining reaction were evaluated by two blinded,
independent observers, including a gynecological pathologist, using the
semiquantitative immunoreactive score (IRS). The IRS was calculated by
multiplication of optical staining intensity including glandular and stromal
staining (graded as 05no reaction, 15weak, 25moderate and 35strong staining)
and the percentage of positive-stained cells (05no positive, 15,25% of the cells,
2525–50% of the cells, 3551–75% of the cells and 45.75% of the cells). The IRS
score derived from both the glandular and the stromal staining of the tissues.
Evaluation and statistical analysis
Western blot bands were analysed via image analysis software (Scion Corporation,
Release Beta 4.0.2, Frederick, MD, USA). Statistical analysis was performed using
the unpaired two-tailed Student’s t-test. Any statistical difference at p,0.05 was
considered significant.
Results
1. Galectin-1 is most highly expressed at the late secretory phase
of eutopic endometrium of healthy women
In order to investigate the galectin-1 expression in eutopic endometrium of
healthy women immunohistochemical analysis in eutopic endometrial tissue
sections of healthy women (10 patients) was performed in three different phases
of the menstrual cycle (proliferative, early secretory and late secretory phase). As
shown in figure 1, galectin-1 expression is higher at late secretory phase
Galectin-1 Expression in Endometriosis
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(Figure 1a). According to IRS Score calculations galectin-1 expression is higher at
the late secretory phase (proliferative phase: 5.125¡0.25 a.u, early secretory phase
6.375¡0.43 a.u, late secretory phase: 7.6875¡0.38 a.u., p,0.05) and it is shown
a 1.24 fold of gal-1 expression at early secretory phase endometrium when setting
the proliferative phase endometrium as control and 1.20 fold of gal-1 expression
at the late secretory phase when setting the early secretory phase endometrium as
control.
2. Galectin-1 overexpression in endometriosis (ectopic
endometrium)
In order to investigate the galectin-1 expression levels in eutopic endometrium of
healthy women (n53), in eutopic and ectopic endometrium of endometriotic
women (n53), western blotting (Figure 1b) was performed. When performing
western blotting, it was shown that galectin-1 is overexpressed in ectopic
endometrium (e) compared to eutopic endometrium of endometriotic women
Figure 1. Galectin-1 overexpression in late secretory phase of eutopic endometrium and in
endometriotic sites. 1a: Immunohistochemical expression of galectin-1 expression through the different
phases of the menstrual cycle of the endometrium (A: proliferative, B: early secretory phase, C: late secretory
phase) showing a higher expression pattern at the late secretory phase of the endometrium(C), *p,0.05. 1b:
Western blot immunodetection of galectin-1 (14 kDa) protein expression in eutopic and ectopic endometrium.
Galectin-1 is overexpressed in eutopic endometrium of endometriotic women (ee) when compared to eutopic
endometrium of healthy women (he), *p,0.05 and galectin-1 shows an abundant expression in ectopic
endometrium (e) when compared to eutopic endometrium of the same endometriotic women (ee), **p,0.01.
GAPDH (37 KDa) was used as a house keeping gene.
doi:10.1371/journal.pone.0114229.g001
Galectin-1 Expression in Endometriosis
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(ee) and eutopic endometrium of healthy women (he) (Figure 1b). Concerning
Western blotting analysis: Galectin-1: 0.887¡0.007 a.u in eutopic endometrium
of endometriotic women vs 0.786¡0.005 a.u in eutopic endometrium of healthy
women, 1.12 fold increase, p,0.05, when setting eutopic endometrium of healthy
women as control. Galectin-1: 1.378¡0.003 a.u in ectopic endometrium vs
0.887¡0.007 a.u in eutopic endometrium of endometriotic women, 1.55 fold
increase, p,0.01, when setting eutopic endometrium of endometriotic women as
control.
3. CRH and UCN upregulate galectin-1 expression
3i. Upregulation of galectin-1 expression in Ishikawa cell line
In order to investigate how galectin-1 expression is regulated in Ishikawa cell line
upon stimulation with CRH peptide, western blotting was performed. Cells where
treated with CRH peptide for 0, 2, 8, 24 hrs. Antalarmin, which is a non-peptide,
synthetic, exogenous antagonist of CRHR1 [43], had been used at the time points
where higher expression of galectin-1 was shown (8 hrs and 24 hrs of CRH
peptide+Antalarmin). As a result, it was shown that CRH upregulated galectin-1
expression in Ishikawa cell line (Figure 2a) mostly at 8 hrs and 24 hrs of
stimulation, time dependently and this was mediated by CRHR1. Antalarmin
blocked the upregulative effect of CRH on galectin-1 expression mostly at 24 hrs
of stimulation in Ishikawa cell line. (Galectin-1 expression in Ishikawa cell line –
CRH peptide stimulation for 0 hrs: 0.8¡0.007, 2 hrs: 0.78¡0.004 a.u, 8 hrs:
0.9¡0.006 a.u, 24 hrs: 1.02¡0.018 a.u, 8 hrs+antalarmin: 0.7¡0.004,
24 hrs+antalarmin: 0.15¡0.009). After showing that CRH had an upregulative
effect on galectin-1 expression in Ishikawa cell line, UCN peptide effect on
galectin-1 expression had been tested at the same time points of stimulation (0, 2,
8, 24 hrs) in the same cell type. UCN peptide caused an increase in galectin-1
expression mostly at 8 hrs of stimulation in Ishikawa cell line (Figure 2b).
(Galectin-1 expression in Ishikawa cell line – UCN peptide stimulation for 0 hrs:
1.01¡0.006, 2 hrs: 0.97¡0.003 a.u, 8 hrs: 1.33¡0.02 a.u, 24 hrs:
0.88¡0.03 a.u).
3ii. Upregulation of galectin-1 expression in macrophages
In order to investigate how galectin-1 expression is regulated in macrophages
upon stimulation of these cells with CRH peptide, western blotting was
performed. Cells were treated with CRH peptide for 0, 2, 8, 24 hrs. Antalarmin,
which is a non-peptide, synthetic, exogenous antagonist of CRHR1, had been used
at the time points where higher expression of galectin-1 was shown (8 hrs and
24 hrs of CRH peptide+Antalarmin). As a result, it was shown that CRH
upregulated galectin-1 expression in macrophages mostly at 24 hrs of stimulation
(Figure 3a) time dependently and this was mediated by CRHR1. Antalarmin
blocked the upregulative effect of CRH on galectin-1 expression in a higher way at
24 hrs of stimulation in macrophages. (Galectin-1 expression in macrophages -
CRH peptide stimulation for 0 hrs: 0.05¡0.0008, 2 hrs: 0.21¡0.001 a.u, 8 hrs:
Galectin-1 Expression in Endometriosis
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0.4¡0.001 a.u, 24 hrs: 0.47¡0.008 a.u, 8 hrs+antalarmin: 0.04¡0.0006,
24 hrs+antalarmin: 0.01¡0.001). After showing that CRH had an upregulative
effect on galectin-1 expression in macrophages, UCN peptide effect on galectin-1
expression had been tested at the same time points of stimulation (0, 2, 8, 24 hrs)
in both cell types. UCN peptide caused an increase in galectin-1 expression mostly
at 24 hrs of stimulation in macrophages (Figure 3b). (Galectin-1 expression in
macrophages – UCN peptide stimulation for 0 hrs: 0.7¡0.01, 2 hrs:
1.21¡0.02 a.u, 8 hrs: 1.37¡0.018 a.u, 24 hrs: 1.81¡0.03 a.u).
Figure 2. Galectin-1 is upregulated in Ishikawa cell line upon CRH and UCN stimulation and this is mediated through CRHR1. Western blot
immunodetection of galectin-1 (14 kDa) protein expression in Ishikawa cell line, regulated by CRH and UCN neuropeptides. GAPDH (37 KDa) was used as
a house keeping gene. 2a: In Ishikawa cell line, galectin-1 expression is upregulated by CRH, showing a higher expression at 8 hrs and 24 hrs of
stimulation. When antalarmin is added, galectin-1 shows an impaired expression mostly at 24 hrs of stimulation. 2b: In Ishikawa cell line, galectin-1 is
upregulated by UCN, showing a higher expression at 8 hrs of stimulation.
doi:10.1371/journal.pone.0114229.g002
Figure 3. Galectin-1 is upregulated in macrophages upon CRH and UCN stimulation and this is
mediated through CRHR1. Western blot immunodetection of galectin-1 (14 kDa) protein expression in
macrophages, regulated by CRH and UCN neuropeptides. GAPDH (37 KDa) was used as a house keeping
gene. 3a: In mice macrophages, galectin-1 expression is upregulated by CRH mostly at 24 hrs and
Antalarmin effect is stronger at 24 hrs. 3b: In mice macrophages, galectin-1 expression is mostly upregulated
by UCN at 24 hrs.
doi:10.1371/journal.pone.0114229.g003
Galectin-1 Expression in Endometriosis
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Discussion
In this study, we show for the first time that gal-1 is abundantly expressed in
endometriotic tissue and that gal-1 is more highly expressed in eutopic
endometrium of women with endometriosis compared to healthy women. Gal-1
was also found to be more highly expressed at late secretory phase of eutopic
endometrium. Moreover, the neuropeptides CRH and UCN which are known to
play a critical role in implantation and inflammation, were found to upregulate
gal-1 expression by acting through the CRHR1 in Ishikawa cell line and
macrophages.
Galectin-1 is expressed in endometriotic sites and is
overexpressed in ectopic sites compared to eutopic endometrium
of endometriotic and healthy women. Galectin-1 is more
abundantly expressed in eutopic endometrium of disease women
compared to healthy ones
Galectin-1 has been reported to interfere with inflammation acting both as a pro-
and an anti- inflammatory cytokine. Gal-1 has been strongly linked to cell growth
and apoptosis of monocytes/macrophage [44–46] and was shown to induce
apoptosis of activated immune cells. To this direction, galectin-1 has also been
found to be involved in cell functions that characterize inflammatory responses
such as in cell adhesion, chemotaxis and antigen presentation and apoptosis
[47, 48] regulating the immune response. Of note is the fact that endometriosis is
widely accepted as an inflammatory process: several proteins including growth
factors, integrins, cadherins and lectins have been accounted for, being related to
cell migration, invasion, angiogenesis, immune functions and apoptosis [49]. The
anti-inflammatory properties of galectin-1 have been examined in several states of
chronic inflammation and autoimmunity including autoimmune encephalo-
myelitis, arthritis, colitis, hepatitis, diabetes and chronic pancreatitis [50]. The
finding of this current study, that galectin-1 is expressed in endometriotic sites, it
is of high importance as it may regulate several immune functions concerning the
pathogenesis of the disease and by being highly expressed in endometriotic sites,
promoting T cell apoptosis, it could be hypothesized that gal-1 favors the
persistence, establishment and immune escape of endometriotic tissue in ectopic
sites. In addition, galectin-1 stimulates proliferation of vascular endothelial cells
[51], so by being expressed in ectopic sites, it could hypothesized that it could
facilitate the endometriotic tissue vascularogenesis, favoring the persistence of the
disease. Moreover, in this study, it is found that galectin-1 is much more highly
expressed in ectopic rather than eutopic endometrium of both endometriotic and
healthy women and it could be hypothesized that galectin-1 decreased expression
in eutopic endometrium compared to ectopic one of disease women indicates that
its function outside the uterus, referring to adhesion formation and pain, might
be strengthened. More experiments will be needed to clarify these hypotheses.
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To further investigate the implication of gal-1 in reproduction defects of
endometriotic women, we investigated galectin-1 expression in eutopic endo-
metrium of endometriotic women compared to that of healthy women. We found
that gal-1 expression is higher in eutopic endometrium of women with
endometriosis compared to healthy ones. Taking into account the fact that gal-1
has been considered an important regulator of implantation our finding could
indicate this increase of galectin-1 as a possible explanation to the endometriosis-
related infertility. To this direction, the herein reported gal-1 upregulation of
eutopic endometrium in case of endometriosis is in accordance with the
established theory suggesting that several differences between eutopic endome-
trium of healthy women and endometriotic women have been correlated to
infertility. These differences, apart from affecting fertility, are at the same time
considered favourable for the endometrium to adhere, grow, and spread outside
the uterine cavity [4, 52]. In addition, our finding expands the current perception
upon galectins’ involvement in the pathophysiology of endometriosis, since until
recently only galectin-3 had been shown to be significantly overexpressed in the
eutopic endometrium of endometriotic women compared to the endometrium of
healthy women [17].
We show also here that galectin-1 is expressed in endometrium at the late
secretory phase and by decidual stromal cells. Decidualization and embryo
implantation are affected by several endocrine, paracrine and autocrine factors
such as hormones, cytokines and growth factors. As mentioned above, galectin-1
can act as an inflammatory cytokine involved in cell growth and macrophage
function [47] [51] [44, 45]. However, the increased expression of apoptotic gal-1
in brain, placenta and other organs of the reproductive tract indicates that gal-1
might lead to T cell death, protecting those tissues from damage due to
proinflammatory cytokines [51]. Galectin-1 has a similar expression pattern in
placentas and extraembryonic membranes and it has also been linked to human
trophoblast cell invasion mechanisms [16]. Additionally, galectin-1 being under
the control of ovarian steroids [15], influences blastocyst implantation [53] and
trophoblast invasion [54] mediating the maternal-embryonic immune/endocrine
cross-talk, as well as placentation [16, 55]. The deranged gal-1 expression seems to
negatively affect pregnancy outcome. Being highly expressed in human third
trimester placentas and extraembryonic membranes, it is further upregulated in
placentas of women with preeclampsia and in extraembryonic membranes in cases
of chorioamnionitis. Interestingly, in abortions galectin-1 expression was reported
to be decreased [56], with circulating gal-1 being marginally detected [54]. To the
same direction, knock out mice of galectin-1 showed a higher rate of fetal loss in
allogenic mating. All above published data together with our findings showing
that gal-1 is differentially expressed in eutopic endometrium of endometriotic
women and in eutopic endometrium of healthy women, suggest that gal-1 might
be involved in implantation failure and thus infertility in case of endometriosis.
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CRH and UCN upregulate galectin-1 expression in Ishikawa cell
line and macrophages. The CRH upregulative effect is mediated
through CRHR1
We then examined how CRH and UCN regulate galectin-1 expression in an
endometrial adenocarcinoma cell line, used as a eutopic epithelial endometrium
model, aiming to further elucidate the role of these molecules in eutopic
endometrium and infertility problems of women with endometriosis. We also
examined these factors in macrophages which represent an important cell type in
inflammation since endometriosis is a benign inflammatory disease. For the first
time we show that CRH and UCN upregulate galectin-1 expression in Ishikawa
cell line and macrophages and this effect is mediated through CRHR1.
The finding that CRH and UCN upregulate galectin-1 expression in Ishikawa
cell line is of high importance since Ishikawa cell line is an in vitro model for
endometrial endocrinology. That galectin-1 was found to be upregulated by
neuropeptides that are expressed in eutopic and ectopic endometrium is also
correlated with the finding showing that galectin-1 is overexpressed in
endometriotic tissue. CRH, UCN have been found to be less expressed in eutopic
endometrium of endometriotic women compared to ectopic endometrium [42].
In the same study, we also showed that CRH R1 and CRHR2 are significantly
more expressed by the eutopic endometrium of women with endometriosis
compared to the corresponding eutopic endometrium of healthy women [42],
implying an increased CRH effect on the eutopic endometrium of women with
endometriosis. To this direction, the significantly elevated gal-1 expression by the
eutopic endometrium in case of endometriosis compared to healthy controls is
thus in line with the proposed CRH-mediated gal-1 expression. The higher the
effect CRH exerts on endometrial epithelial cells, the higher gal-1 expression is.
Therefore it could be assumed that there is an autocrine or paracrine regulative
network between CRH and gal-1 in the endometrium.
Galectin-1 is expressed in a variety of cells in central and peripheral immune
sites including T cells, macrophages and activated B cells and modulates their
functions and apoptosis [45, 51]. The fact that galectin-1 expression is upregulated
in macrophages upon stimulation of CRH and UCN reveals new immunomo-
dulatory roles of these cytokines in macrophages which are known to accumulate
in endometriotic sites.
The upregulation of galectin-1 expression by CRH and UCN in macrophages
indicates a new local gal-1-related immunomodulatory effect promoting a
macrophage-mediated facilitation of endometriotic implants’ establishment by
stimulation of endometrial cell proliferation, tissue remodeling and increased
angiogenesis on the ectopic endometrial sites [57, 58]. Apart from that, gal-1
upregulation per se could lead to a locally increased apoptosis of activated T cells,
contributing to local immune-escape and thus persistence of the endometriotic
tissue.
In conclusion, it is the first time that galectin-1 has been shown to be
overexpressed in endometriotic tissue. Galectin-1 showed an abundant expression
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in ectopic endometrium rather than in eutopic endometrium of endometriotic
women suggesting that this protein could play a vital role in the pathogenesis of
the disease. Moreover, gal-1 increased expression in eutopic endometrium of
endometriotic women compared to healthy ones, could possibly indicate its
implication in endometriotic women’s infertility profile, as gal-1 is a crucial
immune factor involved in implantation and decidualization which expression is
altered in a pathological condition such as endometriosis characterised by altered
endometrium. CRH and UCN have been found to upregulate galectin-1
expression in Ishikawa cell line and macrophages. As these neuropeptides causing
these upregulative effects and galectin-1 which is regulated by them are implicated
in inflammatory procedures such as endometriosis and in reproductive functions,
these results could possibly set new light to the immune disequilibrium of
endometriosis and the infertility profile of endometriotic women. Finally, based
on these results, showing that the CRH upregulative effect on galectin-1 is
mediated by CRHR1, the potential use of Antalarmin could be reinforced in
accessing the immune disequilibrium noticed in eutopic and ectopic endome-
trium of women with endometriosis.
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